Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hutchmed China Ltd ADR
(NQ:
HCM
)
18.47
-1.18 (-6.01%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Hutchmed China Ltd ADR
< Previous
1
2
3
Next >
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
September 29, 2023
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
September 12, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
September 11, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
August 28, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
August 20, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Reports 2023 Interim Results and Provides Business Updates
July 31, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study
July 19, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Changes to Board of Directors and Technical Committee
July 13, 2023
Ms Ling Yang to replace Mr Lefei Sun as Non-executive Director; Professor Solange Peters appointed as Special Advisor to the Technical Committee
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China
July 09, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED to Announce 2023 Half-Year Financial Results
June 26, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
June 15, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
June 15, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings
June 09, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
May 25, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting
May 25, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
May 18, 2023
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
May 15, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
HUTCHMED Announces Board of Directors and Board Committee Membership
May 12, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees
May 10, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
May 09, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
April 17, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023
April 11, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Intended Retirement of Independent Non-executive Director
April 11, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations
April 04, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
March 30, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
March 14, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Confirms No Assets Held at Silicon Valley Bank
March 12, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
February 28, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China
February 27, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED to Announce 2022 Final Results
January 31, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.